QL1706 plus chemotherapy before cervical cancer surgery
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether adding a new immunotherapy drug called QL1706 to standard chemotherapy before surgery can help treat early-stage cervical cancer better. The goal is to shrink tumors and improve outcomes for patients who haven't had immune therapy before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Female, ages 18–65
- Diagnosed with cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma (confirmed by biopsy)
- Early-stage cervical cancer (FIGO stage IB1, IB2, or IB3) – meaning cancer is confined to the cervix or slightly beyond
- Had a pelvic MRI scan before enrollment
- Good overall health and able to tolerate treatment (ECOG score 0–2)
- Normal kidney, liver, and bone marrow function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called QL1706 for people with cervical cancer that has spread and no longer responds to PD-1/PD-L1 therapy. It may offer a new treatment option if you have tried this type of immunotherapy before.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy before surgery for early-stage triple-negative breast cancer. It aims to see if the treatment shrinks the tumor enough to make surgery more effective.
This trial tests a combination of an immunotherapy drug (QL1706) plus chemotherapy given before surgery to shrink early high-risk triple-negative breast cancer. The goal is to see if this treatment can improve the chance of a complete response (no cancer left at surgery).
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy before surgery for cervical cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests if giving chemotherapy plus an immunotherapy drug before surgery can help shrink tumors and improve outcomes for patients with stage IB2 cervical cancer that has not been treated yet. It might be an option if you have a specific type of cervical cancer that shows a certain protein (PD-L1) on your tumor cells.
This trial is testing whether adding the immunotherapy drug QL1706 to standard chemotherapy before surgery can improve outcomes for women with a certain type and stage of cervical cancer. It is for women whose cancer has not been treated yet and who are healthy enough for the treatment.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.